Bayer, J&J wrap positive PhIII cardio study for Xarelto early, looking to beef up its market
Back in the fall of 2012, its sights set on building a blockbuster flagship drug out of its anticoagulant Xarelto, Bayer and its partners at J&J set out to do a massive study to see if the drug could help prevent major cardiovascular events like stroke, myocardial infarction and death in high risk patients with coronary artery disease or peripheral artery disease.
Today, a little more than 4 years and 27,000-plus patients later, investigators say that they hit the primary endpoint well ahead of schedule. Now they’re ending the trial early and launching an extension study where they will continue to dose patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
